Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic Sudden Sensorineural Hearing Loss

NCT05776459 is registered in ClinicalTrials.gov with AudioCure Pharma GmbH as lead sponsor.

NCT NCT05776459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic Sudden Sensorineural Hearing Loss
Lead sponsor
AudioCure Pharma GmbH
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 13, 2022
Completion date
July 31, 2026
Enrollment
210 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

hearing loss, sensorineural